Astonishingly, it is rapidly becoming apparent in the aftermath of the Dr. Bryan Ardis revelations about snake venom origins for covid-19 that many people — even some in alt media — are completely unaware that snake venom is commonly used as the starting point for pharmaceutical research.
Earlier today, a UK company literally named “Venomtech” announced a massive venom peptide and venom fragment library to be used for drug discovery by pharmaceutical companies (as well as pesticide used for agricultural companies).
The news was widely covered in the biotech media, including at News-Medical.net, which published the announcement, “Venomtech announces new drug development collaboration with Charles River.”
From that announcement:
Venomtech is collaborating with Charles River Laboratories, International Inc. to help drug developers explore venom-derived compounds for a wide range of therapeutic targets. This newly formed collaboration will bring together Venomtech’s biology expertise and vast venom-derived peptide library, with Charles River’s drug development and screening knowhow, providing pharmaceutical manufacturers with a one-stop service to explore this unique natural resource.
Venomtech’s Targeted-Venom Discovery Array™ (T-VDA™) libraries provide researchers with a straightforward solution to rapidly screen thousands of individual venom fragments, with each array specifically designed to maximise hits for a specific target.
The announcement carries this statement from Venomtech CEO Paul Grant: